Huiping Xu

发表

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects

Weiwei Tan, Huiping Xu, M. O’Gorman, 2015, European Journal of Clinical Pharmacology.

Pharmacodynamics of Selective Androgen Receptor Modulators

Duane D. Miller, K. Veverka, J. Dalton, 2003, Journal of Pharmacology and Experimental Therapeutics.

Pharmacodynamics of Selective Androgen Receptor Modulators ( SARMs )

Duane D. Miller, K. Veverka, J. Dalton, 2002 .

Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis

D. Bostwick, J. S. Morris, G. Combs, 2010, Dose-response : a publication of International Hormesis Society.

Noninvasive Prediction of Prostatic DNA Damage by Oxidative Stress Challenge of Peripheral Blood Lymphocytes

D. Bostwick, J. S. Morris, G. Combs, 2007, Cancer Epidemiology Biomarkers & Prevention.

Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.

Duane D. Miller, J. Dalton, Jun Yang, 2006, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer.

Duane D. Miller, J. Dalton, E. Hurh, 2004, Bioorganic & medicinal chemistry letters.

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.

Suzanne F. Jones, H. Burris, J. Infante, 2011, European journal of cancer.

Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor

Duane D. Miller, J. Dalton, L. Kirkovsky, 2003, Journal of Pharmacology and Experimental Therapeutics.

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants

Y. Pithavala, Huiping Xu, L. James, 2019, Advances in Therapy.

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

M. Grever, J. Byrd, I. Flinn, 2009, Leukemia & lymphoma.

Combined Pan‐HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study

G. Giaccone, P. Jänne, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Weiwei Tan, Huiping Xu, M. O’Gorman, 2015, Journal of clinical pharmacology.

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer

A. El-Khoueiry, J. Chakrabarti, B. El-Rayes, 2018, Cancer Chemotherapy and Pharmacology.

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

J. Hainsworth, K. Pierce, C. Langer, 2007, Cancer Chemotherapy and Pharmacology.

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

D. Camidge, S. Shreeve, H. Burris, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results

Suzanne F. Jones, H. Burris, J. Infante, 2008 .

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants

Weiwei Tan, Kyle T. Matschke, Huiping Xu, 2021, Clinical pharmacology in drug development.

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants

S. Nepal, Huiping Xu, M. O’Gorman, 2021, Clinical pharmacology in drug development.

Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies.

S. Shreeve, K. Pierce, D. Yin, 2010 .

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, H. Burris, J. Infante, 2008 .

A phase I clinical, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with advanced solid tumors

Suzanne F. Jones, D. Camidge, H. Burris, 2008 .

Abstract A86: Design, synthesis, and SAR of focal adhesion kinase (FAK) inhibitors

Matthew D. Wessel, Jing Lin, K. Coleman, 2009 .

Pharmacodynamics of Selective Androgen Receptor Modulators

Duane D. Miller, K. Veverka, J. Dalton, 2003, Journal of Pharmacology and Experimental Therapeutics.

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects

Weiwei Tan, Huiping Xu, M. O’Gorman, 2015, European Journal of Clinical Pharmacology.